The reduction of body weight with liraglutide, a once-daily human GLP-I analogue for type 2 diabetes, primarily comes from fat tissue and the fat tissue lost is predominantly visceral fat
Main Authors: | Jendle, J, Nauck, M, Matthews, D, Frid, A, Hermansen, K, During, M, Zdravkovic, M, Strauss, B, Garber, A |
---|---|
Format: | Journal article |
Published: |
2008
|
Similar Items
-
Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue.
by: Jendle, J, et al.
Published: (2009) -
Liraglutide, a once-daily human GLP-1 analogue, in type 2 diabetes provides similar glycaemic control with reduced body weight compared with glimepiride when added to metformin
by: Hermansen, K, et al.
Published: (2008) -
Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.
by: Nauck, M, et al.
Published: (2009) -
Distinct Influence of Hypercaloric Diets Predominant with Fat or Fat and Sucrose on Adipose Tissue and Liver Inflammation in Mice
by: Caíque S. M. Fonseca, et al.
Published: (2020-09-01) -
Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes
by: Nauck, M, et al.
Published: (2009)